Transient punctuate enhancing lesions preceding natalizumab-associated progressive multifocal leukoencephalopathy

J Neurol Sci. 2014 Nov 15;346(1-2):364-5. doi: 10.1016/j.jns.2014.09.007. Epub 2014 Sep 16.

Authors

Guillaume Taieb¹, Dimitri Renard², Eric Thouvenot², Giovanna Servillo³, Giovanni Castelnovo²

Affiliations

¹ Department of Neurology, CHU Nîmes, Hôpital Caremeau, Place du Pr Debré, 30029 Nîmes Cedex 4, France. Electronic address: taiebguillaume@gmail.com.
² Department of Neurology, CHU Nîmes, Hôpital Caremeau, Place du Pr Debré, 30029 Nîmes Cedex 4, France.
³ Department of Medical, Surgical Health Sciences, Cattinara Hospital, University of Trieste, Strada di Fiume 447, 34149 Trieste, Italy.

PMID: 25241939
DOI: 10.1016/j.jns.2014.09.007

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Brain / pathology*
Female
Humans
Immunologic Factors / adverse effects*
Immunologic Factors / therapeutic use
Leukoencephalopathy, Progressive Multifocal / chemically induced
Leukoencephalopathy, Progressive Multifocal / pathology*
Magnetic Resonance Imaging
Middle Aged
Multiple Sclerosis, Relapsing-Remitting / drug therapy
Natalizumab

Substances

Antibodies, Monoclonal, Humanized
Immunologic Factors
Natalizumab